Ultragenyx Pharmaceutical Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Emil D. Kakkis
- Full Time Employees
- 1,294
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Leveroni Court Novato CA United States of America 94949
- IPO Date
- Jan 31, 2014
- CIK
- 0001515673
- Website
- ultragenyx.com
- Similar Companies
- Business
- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and ultrarare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company offers approved products including Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii for mucopolysaccharidosis VII; and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders; alongside a robust pipeline targeting conditions such as Angelman syndrome with GTX-102. Ultragenyx operates globally, with commercial presence in North America, Europe, and select international markets, serving patients through specialized support programs like UltraCare. In recent developments, Ultragenyx sold a portion of future North American royalties on Crysvita to OMERS Life Sciences for $400 million in November 2025; reported third quarter 2025 financial results with total revenue guidance of $640 million to $670 million; dosed the first patient in the Aurora study for GTX-102 in Angelman syndrome in October 2025; and appointed Eric Olson as Chief Business Officer in September 2025.
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rare disease families find roadmap to drug development at bootcamps
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
There's a New Rare-Earth Stock. Here's What Makes It Stand Out.
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts
BROAD ARROW AUCTIONS TO OFFER EXTREMELY RARE GORDON MURRAY AUTOMOTIVE T.50 VIA LIVE AUCTION DURING THE CALIFORNIA MILLE